REVERSIBLE CARDIAC DYSFUNCTION ASSOCIATED WITH INTERFERON ALFA THERAPY IN AIDS PATIENTS WITH KAPOSIS SARCOMA
REVERSIBLE CARDIAC DYSFUNCTION ASSOCIATED WITH INTERFERON ALFA THERAPY IN AIDS PATIENTS WITH KAPOSIS SARCOMA
复制标题
DOI：
10.1056/nejm198911023211806
复制
发表时间：
1989-11-02
影响因子：
158.5
通讯作者：
LANE, HC
中科院分区：
文献类型：
--
作者：
DEYTON, LR;WALKER, RE;LANE, HC
INTERFERON alfa is a leukocyte-derived glycoprotein with immunomodulatory, antiproliferative, and antiviral properties. Recombinant interferon alfa has been approved by the Food and Drug Administration for the treatment of Kaposi's sarcoma, hairy-cell leukemia, and condyloma acuminatum.1,2In addition, interferon alfa has recently been shown to have antiretroviral effects in the early stages of human immunodeficiency virus type 1 (HIV-1) infection in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi's sarcoma.3,4Well-documented adverse effects of interferon therapy include a flu-like syndrome with fever, chills, and myalgias; malaise; anorexia; fatigue; bone marrow suppression; elevated levels of aminotransferase; and gastrointestinal discomfort. Neurologic and . . .
